ITM reports more Phase 3 radiopharma data in challenge to Novartis’ Lutathera

Elizabeth Cairns

Senior biopharma journalist

ITM Isotope Technologies Munich’s radiopharma candidate reduced neuroendocrine tumor patients’ risk of progression or death by a third compared with standard therapy, according to pivotal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ITM reports more Phase 3 radiopharma data in challenge to Novartis’ Lutathera

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Novo Nordisk looks into starting GLP-1 drug trials for addiction

No news is good news? Merck KGaA quiet on potential SpringWorks takeover

Trump administration reverses lease termination for major FDA quality lab in St. Louis

Judge grants new nationwide block on NIH payment cuts

Novo Nordisk slashes Wegovy price by nearly two-thirds for cash-paying patients

The perfect storm: Why everything is in place for 2025 to be the year of GxP AI

ITM re­ports more Phase 3 ra­dio­phar­ma da­ta in chal­lenge to No­var­tis’ Lu­tathera

Senior biopharma journalist

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

ITM reports more Phase 3 radiopharma data in challenge to Novartis’ Lutathera